NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The present pharmacokinetic (PK)-pharmacodynamic (PD) study will explore the toxicity and
antileukemic response during the initial 3 months of individualised therapy of children and
young adults with acute lymphoblastic leukemia (ALL). The investigators will on an individual
toxicity-titrated basis attempt to increase the dose intensity of the 6-mercaptopurine used
in the two-months post-remission treatment phase of lower risk childhood ALL. This will be
performed together with continuous PEG-ASP (every 2nd week) and interspersed HD-MTX (5 g/m^2)
every 3rd week. Thus, the trial will also test the feasibility of this particular drug
combination.